# Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus

> **NCT04582136** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 146 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04582136
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-04
- **Primary completion:** 2025-04-21
- **Final completion:** 2026-01
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582136, "Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04582136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*